News

The analysis from a randomized clinical trial shows clinically meaningful, statistically significant improvements in daily living and quality of life in essential tremor when using the Felix NeuroAI™ Wristband (MINNEAPOLIS, BUSINESS WIRE) – Fasikl, a trailblazing neuro-AI company redefining the intersection of advanced bioelectronic medicine and artificial intelligence (AI), today announced the publication of data…

(MINNEAPOLIS, Minn.) September 10, 2025 – Fasikl has closed a $26.5 million Series B funding round to accelerate the development and commercialization of next-generation AI therapeutics. The proceeds will support R&D efforts aimed at enhancing efficacy, expanding clinical applications, and improving user experience for upcoming AI therapeutic products targeting essential tremor and other neurological disorders. Funds…

Bloomington’s Fasikl is looking to commercialize its AI-powered wristband treating essential tremor. The device just received FDA clearance. (MINNEAPOLIS, The Minnesota Star Tribune) – Zhi Yang, CEO of Fasikl, recently spoke about the company’s journey from gaming technology to developing a groundbreaking medical device for essential tremor. He described the creation of the Felix NeuroAI™…

Powered by recent breakthroughs in AI technologies, Felix offers a noninvasive, drug-free alternative to surgery and medications, providing all-day relief for adults living with essential tremor (MINNEAPOLIS, BUSINESS WIRE) – Fasikl, a trailblazing neuro-AI company redefining the intersection of advanced bioelectronic medicine and artificial intelligence (AI), today announced that the U.S. Food and Drug Administration…

(MINNEAPOLIS, Minn.) May 21, 2025 – Zhi Yang, CEO of Fasikl, presented at the National Academy of Engineering Regional Meeting at Medtronic Mounds View. The event explored recent advances and future directions in Transforming Healthcare at the Intersection of AI and Medical Devices. Zhi highlighted Fasikl’s leadership in AI therapeutics, showcasing how AI enables personalized, adaptive…

Wristband is a first-of-its-kind investigational wearable designed to provide dynamic, all-day, personalized relief for people with essential tremor (ET); powered by advanced AI to continuously adapt stimulation based on real-time feedback. TRANQUIL study results presented in late-breaker at the 2025 American Academy of Neurology (AAN) annual meeting demonstrate clinically meaningful improvements in ET symptoms and…

(MINNEAPOLIS, Minn.) January 7, 2025 – Fasikl is thrilled to announce our enrollment in the Google for Startups Cloud Program. This prestigious program empowers us to accelerate our position using Google’s leading AI technology and solutions. As an AI startup pioneering Cloud-AI driven therapies, Fasikl has been granted $300,000 in Google Cloud credits along with…

(MINNEAPOLIS, Minn.) September 10, 2024 – Fasikl closes an $18.3 million A+ round investment to develop AI-driven therapeutic technologies. The funds will be allocated to R&D and clinical trials for expanding indications. The round is co-led by iSeed and Tailwinds Ventures.

(MINNEAPOLIS, Minn.) August 4, 2024 – Fasikl presented results from the pilot study of its Felix TM NeuroAI TM Wristband in patients with Essential Tremor at the 3rd Annual Advanced Therapeutics in Movement &  Related Disorders (ATMRD) Congress held by the Parkinson & Movement Disorder (PMD) Alliance in Washington, DC, in June 2024. FelixTM NeuroAITM…

Wearable technology provides all-day tremor relief in studies (MINNEAPOLIS, Minn.) January 29, 2024 – Fasikl, a Minnesota-based neuro-AI company, announces the completion of two prospective studies for their Felix NeuroAI™ Wristband, a wearable technology specifically engineered to offer all-day relief from tremors for adults suffering from a condition known as essential tremor. Results from the…

Platform shows promise in facilitating brain-machine communication and providing pain relief for patients (MINNEAPOLIS, Minn.) July 11, 2023 – Fasikl, a Minnesota-based neuro-AI company, is developing AI-supported neural technologies with the mission of making a profound difference in the wellbeing of patients’ lives. Building on a decade of intensive research, the company has developed an…

(MINNEAPOLIS, Minn.) July 12, 2023 – The U.S. Food and Drug Administration has granted “breakthrough device designation” to two products developed by med-tech startup Fasikl.

(MINNEAPOLIS, Minn.) March 3, 2023 – Fasikl has closed a $10 million Series A equity investment to advance its AI-driven therapeutic technologies. The funding will support continued research and development and a pivotal clinical trial to pursue FDA clearance.

(MINNEAPOLIS, Minn.) November 1, 2021 – Fasikl has closed a $5 million Pre- Series A equity investment to accelerate its R&D in AI-driven therapeutic technologies. The funding will support continued research and development and launch a pilot clinical trial to establish a regulatory pathway for AI-based therapeutics.